Image credit Weight loss is an incredible journey; if you’ve been through it, you know how frustrating and overwhelmin ...

Brands like Kourtney Kardashian's Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight ... of the total GLP-1 market, which ...

Originally approved to help with excess weight and obesity, the injectable Wegovy and its sibling-product Ozempic, which is ...

Ozempic and similar drugs are often effective because they produce feelings of satisfaction, in line with the NBC theory of ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...